Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD).

Full DD Report for GLMD

You must become a subscriber to view this report.


Recent News from (NASDAQ: GLMD)

Galmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q3 2018 Results - Earnings Call Transcript
Galmed Pharmaceuticals Ltd (GLMD) Q3 2018 Earnings Conference Call November 5, 2018 08:30 AM ET Executives Paul Arndt - Managing Director, LifeSci Advisors Allen Baharaff - Co-Founder, Chief Executive Officer Yohai Stenzler - Chief Financial Officer Liat Hayardeny - Chief Scien...
Source: SeekingAlpha
Date: November, 05 2018 14:18
Galmed net loss improves in Q3
Galmed ( GLMD ) Q3 results: Revenues: $1.5M. More news on: Galmed Pharmaceuticals Ltd., Healthcare stocks news, Earnings news and commentary, , Read more ...
Source: SeekingAlpha
Date: November, 05 2018 07:52
Galmed beats by $0.12, beats on revenue
Galmed (NASDAQ: GLMD ): Q3 GAAP EPS of -$0.05 beats by $0.12 . More news on: Galmed Pharmaceuticals Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: November, 05 2018 07:05
Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2018 Financial Results
TEL AVIV, Israel , Nov. 5, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, a once-daily, oral therapy for the treatment of nona...
Source: PR Newswire
Date: November, 05 2018 07:00
Key events next week - healthcare
Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: November, 02 2018 10:12
Galmed Pharmaceuticals to Report Third Quarter 2018 Financial Results and Provide Business Update on Monday, November 5
TEL AVIV, Israel , Oct. 29, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy f...
Source: PR Newswire
Date: October, 29 2018 08:30
Galmed Pharmaceuticals to Present at the Cantor Global Healthcare Conference, ROTH Battle of the NASH Thrones Investor Conference and Stifel Healthcare Conference
TEL AVIV, Israel , Sept. 27, 2018 /PRNewswire/ --  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment of nonalcoholic ste...
Source: PR Newswire
Date: September, 27 2018 08:00
NASH Cirrhosis: The Real NASH Epidemic
Introduction Cirrhosis of the liver threatens the lives of millions of people, and other than a risky, expensive, and temporary transplant, it has no treatment. This marks cirrhosis among those diseases with the greatest unmet medical needs. Healthy liver, left, versus cirrhotic liver...
Source: SeekingAlpha
Date: August, 28 2018 14:19
Galmed Pharmaceuticals: Buy This NASH Play?
"Arrogant men with knowledge make more noise from their mouth than making a sense from their mind ." - Amit Kalantri, Wealth of Words Last week was a good one for NASH concerns like Intercept Pharmaceuticals ( ICPT ) . I have received a few inquiries about another smaller potential NASH ...
Source: SeekingAlpha
Date: August, 27 2018 11:33
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2018 Results - Earnings Call Transcript
Galmed Pharmaceuticals Ltd. (GLMD) Q2 2018 Earnings Conference Call August 2, 2018 8:30 AM ET Executives Michael Wood - Investor Relations, LifeSci Advisors Allen Baharaff - Co-Founder, Chief Executive Officer Yohai Stenzler - Chief Financial Officer Liat Hayardeny - Chief Scie...
Source: SeekingAlpha
Date: August, 04 2018 13:41

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-139.358.539.508.36126,144
2018-12-128.229.199.748.22619,690
2018-12-118.397.918.447.8370,565
2018-12-108.528.41048.528.1139,828
2018-12-078.488.518.65668.3579,715

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1326,82151,06752.5212Short
2018-12-12124,920232,43653.7438Short
2018-12-1118,93241,66045.4441Short
2018-12-108,12420,75639.1405Short
2018-12-0714,12941,08234.3922Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GLMD.


About Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD)

Logo for Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD)

Not available

 

Contact Information

     

     

    Current Share Structure

    • Market Cap: $95,317,776 - 05/16/2018
    • Authorized: 50,000,000 - 05/01/2018
    • Issue and Outstanding: 15,473,665 - 05/01/2018

     


    Recent Filings from (NASDAQ: GLMD)

    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 09 2018
    Statement of beneficial ownership of common stock by certain persons
    Filing Type: SC 13GFiling Source: edgar
    Filing Date: April, 16 2018
    Prospectus filed under Rule 424(b)(5)
    Filing Type: 424B5Filing Source: edgar
    Filing Date: April, 04 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: April, 04 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: April, 03 2018
    Registration statement for certain foreign private issuers offered for certain transactions
    Filing Type: F-3Filing Source: edgar
    Filing Date: March, 26 2018
    Annual and transition report of foreign private issuers under sections 13 or 15(d)
    Filing Type: 20-FFiling Source: edgar
    Filing Date: March, 13 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: March, 13 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: February, 14 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: February, 07 2018

     

     


    Daily Technical Chart for (NASDAQ: GLMD)

    Daily Technical Chart for (NASDAQ: GLMD)


    Stay tuned for daily updates and more on (NASDAQ: GLMD)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: GLMD)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GLMD is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of GLMD and does not buy, sell, or trade any shares of GLMD. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/